Hepatitis D: Clinical Trials

6 trials for Hepatitis D, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

6 completed. 6 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 36Completed 6

Follow Hepatitis D: new trials by email Literature Review of Hepatitis D trials Research Report on Hepatitis D

Trials (filtered) newest first · largest first

All 6 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Once Daily Dosing of Lonafarnib Co-administered With Ritonavir for Treatment of Chronic Hepatitis D Virus Infection
Lonafarnib, Ritonavir - Hepatitis D, Chronic
Phase 3CompletedSoroka University Medical Center102021-05-152026-04-30
Study to Assess Efficacy and Safety of Bulevirtide in Participants With Chronic Hepatitis Delta (CHD)
Bulevirtide - Chronic Hepatitis Delta
Phase 3CompletedGilead Sciences1502019-04-172025-08-22
Study of the Efficacy and Safety of Lonafarnib / Ritonavir With and Without Pegylated Interferon -Alfa-2a
Lonafarnib, Ritonavir, PEG IFN-alfa-2a - Hepatitis Delta Virus
Phase 3CompletedEiger BioPharmaceuticals4072018-12-012023-04-14
A Study of Pegasys (Peginterferon Alfa 2a) Alone or in Combination With Tenofovir in Patients With Chronic Hepatitis D.
peginterferon alfa-2a [Pegasys], placebo, tenofovir - Hepatitis D, Chronic
Phase 3CompletedHoffmann-La Roche502010-02-162019-01-14
Efficacy of Peginterferon Alfa-2b in Previously Untreated Subjects With Chronic Hepatitis B and D Co-infection (Study P04603)
Peginterferon alfa-2b (PegIntron, SCH 54031) - Hepatitis D, Chronic, Hepatitis B, Chronic
Phase 3CompletedMerck Sharp & Dohme LLC682005-12-012017-04-06
A Study of Pegylated Interferon (PEG-IFN) Alfa-2a (Pegasys) in Participants With Chronic Hepatitis D (CHD)
Pegylated Interferon (PEG-IFN) alfa-2a - Hepatitis D, Chronic
Phase 3CompletedHoffmann-La Roche312005-10-012016-08-26

Narrower conditions

Hepatitis D, Chronic (5)  ·  Hepatitis B (2)  ·  Hepatitis B, Chronic (1)

Broader conditions

Digestive System Diseases (6)  ·  Hepatitis (6)  ·  Hepatitis, Viral, Human (6)  ·  Infections (6)  ·  Liver Diseases (6)  ·  RNA Virus Infections (6)  ·  Virus Diseases (6)  ·  Chronic Disease (5)  ·  Disease Attributes (5)  ·  Hepatitis, Chronic (5)  ·  Pathologic Processes (5)  ·  Pathological Conditions, Signs and Symptoms (5)  ·  Blood-Borne Infections (2)  ·  Communicable Diseases (2)

Interventions

peginterferon alfa-2a (3)  ·  Ritonavir (2)  ·  lonafarnib (2)  ·  Tenofovir (1)  ·  bulevirtide (1)  ·  myrcludex-B (1)  ·  peginterferon alfa-2b (1)

Sponsors

Hoffmann-La Roche (2)  ·  Eiger BioPharmaceuticals (1)  ·  Gilead Sciences (1)  ·  Merck Sharp & Dohme LLC (1)  ·  Soroka University Medical Center (1)

Countries

Turkey (Türkiye) (3)  ·  Germany (2)  ·  Israel (2)  ·  Italy (2)  ·  New Zealand (2)  ·  Romania (2)  ·  Russia (2)  ·  Sweden (2)  ·  United States (2)  ·  Belgium (1)  ·  Bulgaria (1)  ·  Canada (1)  ·  France (1)  ·  Greece (1)  ·  Moldova (1)

Top investigators

Ohad Etzion, MD (1)

Results publications

PMID 30833068, PMID 37120031, PMID 37407002, PMID 38340811, PMID 39009085, PMID 39648559, PMID 41405233, PMID 41966308

NIH funding

2019 (1)